Houston, TX, (August 26, 2004) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces the expansion of its product development efforts with the addition of Dr. Frederic Kendirgi to the company's scientific staff. Dr. Kendirgi has broad experience in developing Virology and Immunology assays for protein function and expression vectors. He received a Ph.D. in Biochemistry and Molecular Biology from the University of Calgary, and he has authored five scientific papers.
Dr. Yin Chen, CytoGenix Vice President of Research and Development states, "Frederic is an outstanding scientist with an excellent background and he will fit well into our focused discovery efforts providing a continuous flow of new products to complement our two lead candidates. From these targeted efforts, we plan to submit at least two Investigational New Drug applications with the Food and Drug Administration in the next six to nine months."
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has 40 international or US pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Communications Director — Juan Ferreira, (407) 774-9949
